|Articles|August 7, 2012
Mark Zitter, MBA, Discusses Oncology Pathways
Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.
Advertisement
Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs. However, Zitter says that over the next year or so, pathways will not be the dominant factor in oncology management.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
2
MFN Drug Agreements Could Raise Prices Worldwide
3
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
4
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
5